Published

04 Sep 25

Updated

20 Aug 26

Views

31

Not Invested

Fair Value

US$145.92

Share price20 Aug

US$181.1324.1% overvalued

Loading

1Y45.15%

7D8.57%

Inflation And Deglobalization Risks Will Curtail Progress As China Recovers

AN

AnalystLowTarget

Analyst Low Target compiles bearish analysts opinions to create narratives which represent one standard deviation below the consensus price target, using forecasted revenue and earnings figures, as well as the transcripts of earnings calls.

Published

04 Sep 25

Updated

20 Aug 26

Views

31

Not Invested

Shared on 20 Aug 26

Fair value Increased 2.76%

RGEN: Cancer Vaccine Hype And BioLife Deal Will Test Overstretched Expectations

Repligen is getting fresh attention as investors link its tools to Moderna’s personalized cancer vaccine push, but the market’s expectations look stretched. A planned BioLife Solutions acquisition adds another big test, with integration and execution likely to matter as much as demand.

0 views

Shared on 13 Jun 26

RGEN: Bioprocess Recovery And Training Hub Expansion Will Guide Future Performance

Repligen leans into a rebound in bioprocessing demand, and its new customer training hub in the Netherlands gives drugmakers hands-on access to its tools as it pushes for wider adoption. But with several analysts trimming their expectations, any stumble in execution or a slower pickup in customer spending could keep pressure on the stock.

1 view

Shared on 30 May 26

RGEN: Firmer Bioprocess Backdrop And Hubs Expansion Will Shape Long Term Outlook

Repligen’s outlook gets a lift as the bioprocess market starts to feel steadier, and the company expands hands-on training hubs meant to pull customers closer to its tools. But a wave of lowered targets from more cautious analysts shows the debate now hinges on whether demand really rebounds soon—especially around gene-therapy customers—or takes longer than expected.

2 views

Shared on 11 May 26

Fair value Increased 1.43%

RGEN: Recalibrated Street Expectations And Hubs Expansion Will Shape Long Term Outlook

Analysts now place Repligen's fair value at $142, a $2 adjustment that reflects a mix of recent price target cuts and increases as they weigh updated growth expectations, margins, and P/E assumptions from the latest round of Street research. Analyst Commentary The latest Street research on Repligen shows a split tape, with some firms lifting targets and others cutting them, which nets out to the modest US$2 bump in the aggregated fair value estimate to US$142.

3 views

Shared on 25 Apr 26

Fair value Decreased 13%

RGEN: recalibrated Street Expectations Will Shape Bullish Long Term Outlook

The analyst price target for Repligen has been reduced from about $160.90 to $140.00, as analysts factor in updated assumptions for revenue growth, profit margins, discount rates and future P/E following a mix of recent target cuts and one upward revision across the Street. Analyst Commentary Street research on Repligen over recent months points to a mixed but generally more cautious stance, with several firms trimming price targets while one research house lifted its target.

2 views

Shared on 09 Feb 26

Fair value Increased 0.34%

RGEN: M&A Ambitions And New Resins Portfolio Will Shape Bullish Outlook

Analysts have lifted their price target on Repligen by US$10, citing updated assumptions that reflect revised fair value estimates, a tweaked discount rate, adjusted revenue growth and profit margin expectations, and an updated future P/E multiple. Analyst Commentary Even with the higher price target, some research commentary points to risks that readers should keep in mind when weighing Repligen at current levels.

2 views

Shared on 27 Dec 25

Fair value Increased 22%

RGEN: Process Analytics Momentum And Biopharma Recovery Will Shape Risk Balanced Outlook

Narrative Update We are raising our Repligen fair value estimate from $131.29 to $160.36 per share as analysts lift price targets toward $160 to $165 on better than expected Q3 results, broad-based revenue growth led by Process Analytics, and an improving outlook for biopharma end markets. Analyst Commentary Recent Street research reflects a cautiously constructive stance on Repligen, with higher price targets acknowledging near term execution outperformance while still embedding meaningful risk around sustainability of growth.

3 views

Fair Value vs Share Price

US$145.92

vs US$181.1324.1% overvalued

13.4%

Revenue growth

13.3%

Profit margin

Recent News & Updates

No updates

Recent updates

No updates

Stay ahead on Repligen

Fair value estimate changes
Narrative and analyst updates
Key company announcements

Company analysis

Excellent balance sheet with reasonable growth potential.

Market capUS$10.2b

PB4.8x

Estimated Growth14.7%

Dividend YieldN/A

CEO & management

Olivier Loeillot

CEO

2.4yrs

CEO Tenure

A life sciences company, develops and commercializes bioprocessing technologies and systems in North America, Europe, the Asia Pacific, and internationally.